ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[The function of nuclear factor-erythroid 2-related factor 2 and its association with I-kappa B kinases alpha/beta in a rat model of chronic obstructive pulmonary disease.].

OBJECTIVE: To study the expression of nuclear factor-erythroid 2-related factor 2 (Nrf2) in the bronchial and lung tissues of chronic obstructive pulmonary disease (COPD) rat models and its association with I-kappa B kinases (IKKs).

METHODS: Rat COPD models were established by intratracheal instillation of lipopolysaccharide (LPS) twice and exposure to cigarette smoke daily. The drug intervention group received 15-deoxy-Delta2, 14-prostaglandin J2 (15d-PGJ2) 0.3 mg/kg twice via tail venous injection. Spirometry was conducted and the pathological changes were observed. Antioxidation activities were measured and the expressions of Nrf2, IKKalpha/beta and NF-kappaB p65 were detected by immunohistochemistry and RT-PCR. The differences among groups were calculated by one-way ANOVA, and comparison between groups was made by LSD-t test.

RESULTS: FEV(0.3)/FVC, Cdyn values and antioxidation capacity including total anti-oxidation competence and superoxidase dismutase in the COPD group [(58.8 +/- 2.6)%, (0.14 +/- 0.02) ml/cm H2O (1 cm H2O = 0.098 kPa), (0.20 +/- 0.03) U/ml and (19.6 +/- 2.4) U/ml, respectively] were significantly lower than those in the normal control group [(86.3 +/- 2.5)%, (0.38 +/- 0.02) ml/cm H2O, (3.16 +/- 0.31) U/ml and (56.1 +/- 2.2) U/ml, respectively]. RI values (0.69 +/- 0.17) cm H2Oxml(-1)xs(-1) were significantly higher than that of the normal control group (0.34 +/- 0.06) cm H2Oxml(-1)xs(-1). The above measurements of the drug intervention group [(74.5 +/- 3.9)%, (0.30 +/- 0.04) ml/cm H2O, (1.90 +/- 0.24) U/ml, (39.7 +/- 1.9) U/ml and (0.43 +/- 0.05) cm H2Oxml(-1)xs(-1), respectively] were between the COPD and the control groups, with airflow limitation and pulmonary ventilation improved significantly. Immunohistochemistry showed that, the positive coefficient of Nrf2, IKKalpha/beta and NF-kappaB p65 were increased significantly in the COPD models (3.23 +/- 0.31, 3.80 +/- 0.16 and 3.85 +/- 0.18, respectively), as compared with the control group (0.91 +/- 0.45, 1.17 +/- 0.42 and 1.30 +/- 0.34, respectively). The expression of IKKalpha/beta (2.10 +/- 0.46) and NF-kappaB p65 (2.53 +/- 0.36) in the lungs of the intervention group was between the COPD group and the control group, but the expression of Nrf2 (3.78 +/- 0.22) increased as compared to the COPD group. The results of RT-PCR showed that, the mRNA IOD value of Nrf2, IKKbeta and NF-kappaB p65 increased significantly in the COPD group (0.61 +/- 0.08, 0.89 +/- 0.05 and 0.91 +/- 0.02, respectively), as compared with the control group (0.29 +/- 0.07, 0.30 +/- 0.07, 0.30 +/- 0.07, respectively), while the expression of IKKbeta (0.67 +/- 0.04) and NF-kappaB p65 (0.69 +/- 0.04) in the lungs of the drug intervention group were between the above two groups, and the expression of Nrf2 (0.90 +/- 0.05) increased as compared to the COPD group.

CONCLUSIONS: 15d-PGJ2 was shown to have anti-oxidation and anti-inflammation effects in this COPD model, which may be related to the increase of Nrf2. Nrf2 inhibited the expression of NF-kappaB p65 possibly through the down-regulation of IKKbeta.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app